Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

CHMP Agenda March 23-26; Lilly Halts Trial Enrollments Over COVID-19 Concerns

Here is a brief preview of this blast: The CHMP agenda for this month’s meeting (March 23-26) has been released, and it includes two notable items (high-dose Trulicity Day 120 questions and Biocon/Mylan bs-aspart clock stop extension). Of note, as of the publication of this blast, the March CHMP agenda does not include the "Annex" section, so it is possible that other diabetes-related items are also being reviewed. Separately, Lilly announced it was halting new trial initiation and pausing trial enrollment for most of its clinical studies amid COVID-19 concerns. Below, FENIX provides diabetes-related highlights and insights from the March 2020 CHMP agenda and Lilly announcement.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.